piribedil has been researched along with Chronic Disease in 4 studies
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind, cross-over trial of the effectiveness of piribedil, procyclidine and placebo in the control of parkinsonism induced by fluphenazine decanoate was conducted in sixteen cases of chronic schizophrenia." | 5.04 | A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism. ( Bradley, R; Lamb, P; Mindham, RH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brocco, M | 1 |
| Dekeyne, A | 1 |
| Papp, M | 1 |
| Millan, MJ | 1 |
| Mindham, RH | 1 |
| Lamb, P | 1 |
| Bradley, R | 1 |
| Argenteri, A | 1 |
| Moia, R | 1 |
| Negri, L | 1 |
| Guagliano, G | 1 |
| Bagliani, A | 1 |
| Borri, P | 1 |
2 trials available for piribedil and Chronic Disease
| Article | Year |
|---|---|
A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.
Topics: Chronic Disease; Clinical Trials as Topic; Fluphenazine; Humans; Parkinson Disease; Parkinson Diseas | 1977 |
[Therapeutic acquisitions on chronic obliterating peripheral arterial diseases of the lower limbs].
Topics: Arteriosclerosis Obliterans; Chronic Disease; Clinical Trials as Topic; Humans; Leg; Piribedil; Thro | 1976 |
2 other studies available for piribedil and Chronic Disease
| Article | Year |
|---|---|
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Topics: Aggression; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive | 2006 |
[Piribedil (TF 871) in the treatment of arteriopathies of the lower extremities].
Topics: Adult; Aged; Arteriosclerosis Obliterans; Chronic Disease; Drug Evaluation; Drug Tolerance; Female; | 1979 |